Laquinimod suppress antigen presentation in relapsing–remitting multiple sclerosis: In-vitro high-throughput gene expression study

• Published in: Journal of neuroimmunology Vol. 221; no. 1; pp. 87 - 94
• Main Authors: Gurevich, M., Gritzman, T., Orbach, R., Tuller, T., Feldman, A., Achiron, A.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 15.04.2010
• Subjects: Adult; Allergy and Immunology; Antigen Presentation - drug effects; Antigens, CD - metabolism; Cell subpopulation; Cell Survival; Dose-Response Relationship, Drug; Female; Gene Expression Profiling - methods; Gene Expression Regulation - drug effects; Humans; Immunologic Factors - pharmacology; Killer Cells, Natural - drug effects; Laquinimod; Leukocytes, Mononuclear - drug effects; Leukocytes, Mononuclear - metabolism; Microarray gene expression; Middle Aged; Models, Immunological; Multiple sclerosis; Multiple Sclerosis, Relapsing-Remitting - immunology; Multiple Sclerosis, Relapsing-Remitting - pathology; Neurology; NF-kappaB-Inducing Kinase; Oligonucleotide Array Sequence Analysis - methods; PBMC; Protein Array Analysis - methods; Protein Serine-Threonine Kinases - metabolism; Quinolones - pharmacology; Microarray gene expression; Multiple sclerosis; Laquinimod; PBMC; Cell subpopulation

Laquinimod (LAQ) is a new immunomodulatory drug shown to be effective in the treatment of relapsing–remitting multiple sclerosis (RRMS); however, its molecular target pathways are not well recognized. In this study we characterized in-vitro the molecular effects of LAQ in peripheral blood mononuclea...